New combo therapy aims to save bladders in cancer fight
NCT ID NCT05833867
First seen Mar 29, 2026 · Last updated May 17, 2026 · Updated 7 times
Summary
This early-stage trial tests a drug called sacituzumab govitecan (SG) given alongside a precise type of radiation therapy for people with muscle-invasive bladder cancer. The goal is to see if this combination is safe and can help patients keep their bladder instead of needing surgery. About 20 participants will receive the drug weekly for three cycles, with radiation starting in the second cycle. The study lasts up to 5 years, including treatment and follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44195, United States
Contact
Conditions
Explore the condition pages connected to this study.